Intercept Pharmaceuticals (ICPT) PT Slashed to $125 at FBR Capital; Role in NASH More limited than Expected
Tweet Send to a Friend
FBR Capital analyst Andrew Berens reiterated an Underperform rating on Intercept Pharmaceuticals (NASDAQ: ICPT) while cutting his price target to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
